Estimating the lost benefits of antiretroviral drug use in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 4, 2008, Pages 410-415

  Chigwedere, Pride ^a,b   Seage III, George R ^a   Gruskin, Sofia ^a   Lee, Tun Hou ^a,b   Essex, M ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Harvard AIDS Institute   (United States)

Author keywords

Antiretroviral drug use; Lost benefits; PMTCT; South Africa

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE;

BABY; CHILD; CONTROLLED STUDY; DRUG COST; DRUG USE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SOUTH AFRICA; THEORETICAL MODEL; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; COST OF ILLNESS; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEVIRAPINE; SOUTH AFRICA; TIME FACTORS;

EID: 57649124236     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31818a6cd5     Document Type: Review

References (37)

1. UNAIDS. 2006 Report on the Global HIV/AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2006:505-510.
2. Baleta A. South Africa's AIDS care thrown into confusion. Lancet. 1999;354:1711.
3. Cohen J. South Africa: AIDS researchers decry Mbeki's views on HIV Science. 2000;288:590-591.
4. Minister of Health v Treatment Action Campaign (TAC). 5 SA 721 (CC); 2002.
5. Cullinan K. Global Fund delay costs lives. Health-e; 2003 . Available at: http://www.health-e.org.za/news/article.php?uid=20030410. Accessed July 5, 2007.
6. Essex M, Mboup S. The etiology of AIDS. In: Essex M, Mboup S, Kanki PJ, et al, eds. AIDS in Africa. 2nd ed. New York, NY: Kluwer Academic/Plenum Publishers; 2002:1-10.
7. Cohen J. Fulfilling Koch's postulates. Science. 1994;266:1647.
8. Aschengrau A, Seage GR. The epidemiologic approach to causation. In: Essentials of Epidemiology in Public Health. Sudbury, MA: Jones & Bartlett; 2003:375-401.
9. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-191.
10. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987;317:192-197.
11. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
12. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
13. WHO, UNAIDS. Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and Beyond. Geneva, Switzerland: WHO and UNAIDS; 2006:37.
14. WHO, UNAIDS. Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and Beyond. Geneva, Switzerland: WHO and UNAIDS; 2006:71.
15. UNAIDS. Report on the Global HIV/AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2000, 2002, 2004, 2006. In the 2006 report, UNAIDS suggests that its earlier modeling could have overestimated the prevalence of AIDS and death statistics. We use the estimates from the 2006 report for both 2005 and 2003 estimates, and the 2002 report for 2001 estimates. For the years with no reports, we use the statistic for the estimate after that year.
16. UNAIDS, UNICEF, WHO. Epidemiological fact sheets on HIV/AIDS and sexually transmitted infections: South Africa. WHO; Geneva, Switzerland; 2006. Available at:http://www.who.int/GlobalAtlas/predefinedReports/EFS2006/EFS_PDFs/ EFS2006_ZA.pdf. Accessed November 1, 2006.
17. WHO, UNAIDS. Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and Beyond. Geneva, Switzerland: WHO and UNAIDS; 2006: annex 1,21.
18. Grimwood A, Almeleh C, Hausler H, et al. HIV and tuberculosis update. In: Ijumba P, Padarath A, eds. South African Health Review 2006. Durban, South Africa: Health Systems Trust; 2006:77-94.
19. WHO and UNAIDS. Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and Beyond. Geneva, Switzerland: WHO and UNAIDS; 2006:73.
20. Braitstein P, Brinkhof MW, Dabis F, et al; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC). Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
21. Bachmann MO. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults. AIDS Care. 2006;18:109-120. Erratum in AIDS Care. 2006;18:415-416.
22. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006; 194: 11-19.
23. Actuarial Society of South Africa. ASSA 2003 Summary Statistics. Cape Town, South Africa: Actuarial Society of South Africa; 2005.
24. Department of Health, Republic of South Africa. National HIV and Syphilis Prevalence Survey in South Africa 2005. Pretoria, South Africa: Department of Health; 2006.
25. Meyers T, Moultrie H, Gayle S, et al. Management of HIV-infected children. In: Ijumba P, Padarath A, eds. South African Health Review 2006. Durban, South Africa: Health Systems Trust; 2006:242.
26. UNICEF. Global database on skilled attendant at delivery. The United Nations Children's Fund. Available at:http://www.childinfo.org/areas/ deliverycare/countrydata.php. Accessed July 5, 2007.
27. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
28. WHO. World Health Report. Geneva, Switzerland: WHO; 2006.
29. Newell ML, Coovadia H, Cortina-Borja M, et al, Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:1236-1243.
30. Hoffmann T, Brunner H. Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease. Eur J Health Econ. 2004;5:129-135.
31. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa: a primary data analysis. Cost Eff Resour Alloc. 2006;4:20.
32. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
33. Skordis J, Nattrass N. Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa. J Health Econ. 2002;21:405-421.
34. Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med. 2006;3:e4.
35. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Côte d'Ivoire. N Engl J Med. 2006;355:1141-1153.
36. Abbas UL, Anderson RM, Mellors JW Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J. Acquir Immune Defic Syndr. 2006;41:632-641.
37. Salomon JA, Hogan DR, Stover J, et al. Integrating HIV prevention and treatment: from slogans to impact. PloS Med. 2005;2:e16.